BioCentury | Jun 29, 2018
Clinical News
Summit discontinues DMD program after Phase II miss
...Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the...
...Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100...
...staining in imaged biopsies and safety Status: Development discontinued Milestone: NA Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Ridinilazole...
...Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100...
...staining in imaged biopsies and safety Status: Development discontinued Milestone: NA Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Ridinilazole...